Pharma
Biotech may not be able to fend off M&A in the coming months, experts say
Biotech has worked hard to fend off M&A. In the wake of a bank collapse and a tightening lending market, that could be coming to an end.
Kristen Talman is a former reporter for CFO Brew, covering the world of corporate finance for the Morning Brew. Before joining the Brew, Kristen worked at the Financial Times where she tracked ESG finance for Moral Money, part of SABEW award-winning newsletter team that dove into if money was moving into greener, more equitable, spaces.